Search Results

Galapagos NV and Blood Centers of America announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos’ CAR-T cell therapies through BCA’s network in the U.S.

Galapagos NV announced its first quarter 2024 financial results and provided a business update and outlook for the remainder of 2024.

Galapagos NV announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings held on 30 April 2024 were approved.

Galapagos NV announced the successful completion of the transaction to transfer its Jyseleca® business to Alfasigma S.p.A.

Galapagos NV announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation.

Galapagos NV and Adaptimmune Therapeutics plc announced that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune’s next-generation TCR T-cell therapy targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos’ decentralized cell manufacturing platform.

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress.

Galapagos NV publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders’ Meetings to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm and 3:00 pm, respectively, at the registered office of the Company.

Galapagos NV and Alfasigma S.p.A. announced that they have signed an agreement to transfer Galapagos’ Jyseleca® business to Alfasigma, marking a significant milestone in Galapagos’ transformation into an innovative biotechnology company with a best-in-class research and development pipeline aimed at addressing high unmet patient needs in immunology and oncology.

Galapagos NV to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation -European Hematology Association 6th European CAR T-cell meeting taking place from 15–17 February 2024 in Valencia, Spain.